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Letters to the Editor
1060Reply to: ‘‘New onset diabetes after transplantation: A type
1.5 diabetes or latent autoimmune diabetes of adults?’’To the Editor:
We would like to thank Dr. Eshraghian for his interest in and
insightful comments on our article. Both of us believe that
genetic factor involves in the pathogenesis of new onset diabe-
tes after transplantation (NODAT). Dr. Eshraghian summarized
the association between TCF7L2 gene and diabetes, and
explained the underlying mechanism by the role of TCF7L2 gene
in human pancreatic islets. Here, we would like to make an
additional explanation that TCF7L2 gene also plays a crucial role
in hepatic glucose metabolism by interacting with multiple
gluconeogenic genes and regulating glucose intolerance in the
liver [1,2]. TCF7L2 is important for insulin secretion and also
critical for hepatic glucose production and hepatic insulin
sensitivity. Therefore, in our study, both donor and recipient
TCF7L2 genetic variants were associated with the onset of
NODAT, possibly via the effects on donor liver glucose metabo-
lism and recipient islets.
Dr. Eshraghian presented comprehensive data on a very inter-
esting possible link between NODAT and latent autoimmune dia-
betes in adults (LADA), which would help better understand the
etiology of NODAT. However, there is similarity but also diversity
in the etiology and pathophysiology of NODATs after different
organ transplantation [3]. He pointed out that b-cell dysfunction
rather than insulin resistance is the main cause of NODAT after
kidney transplantation [4], while in liver transplantation, insulin
resistance, especially liver insulin resistance, is considered to
make a great contribution to NODAT [5]. Compared to other
transplanted solid organs (e.g., kidney, heart, lung), the liver
has the particularity that it is the principal organ for carbohy-
drate, protein, lipid and drug metabolism. Therefore, we hypoth-
esized that donors’ phenotype and genotype may affect
metabolic status in liver transplant recipients, and the primary
purpose of our study was to investigate the role of donor liver
in the development of post-liver transplantation complications.
In our previous study, donor CYP3A5 gene polymorphisms were
associated with the metabolism of tacrolimus in liver transplan-
tation [6], and donor rs290487 genetic variant in TCF7L2 gene
increased NODAT risk after liver transplantation [7]. In our mostJournal of Hepatology 20recent study, we showed that donor’s genotype could even con-
tribute to intrahepatic recurrence of hepatocellular carcinoma
after liver transplantation (unpublished data). Taken together,
these ﬁndings provide evidence that donor liver does have a great
inﬂuence on the post-liver transplant complications, and open a
door to evaluate the respective roles of donor and recipient or
even their cross-talk in the outcome after liver transplantation.
LADA is distinguished from type 2 diabetes by the presence of
islet autoantibodies [8]. With great interest, we learn the possible
link between NODAT and LADA. We should admit that NODAT
shares some similarities with LADA in clinical presentation.
However, it is still too early to say whether NODAT could be
categorized into this subgroup because the etiologies of both
NODAT and LADA are unclear. According to the LADA China study
[8], glutamic acid decarboxylase antibody (GADA) positive phe-
notypic type 2 diabetes (<1 year post diagnosis, without insulin
therapy for >6 months, agedP30 years) was considered as LADA.
Circulating islet autoantibodies are essential in the diagnosis of
LADA. Up to now, the most important evidence to prove the asso-
ciation between NODAT and LADA is from Lohmann et al. [9], as
mentioned by Dr. Eshraghian. In a cohort of 58 patients, they
found that islet cell autoantibodies-positive patients with tacrol-
imus treatment were more prone to have NODAT after liver
transplantation [9]. Other evidence is from genetics research
indicating that both diseases were related to TCF7L2 gene poly-
morphisms [7,10]. However, other important points for the diag-
nosis of LADA, such as time to insulin dependence, age and body
mass index (BMI), are unspeciﬁc and anthropogenic in NODAT.
For instance, perioperative or in-hospital hyperglycemia is rou-
tinely treated with insulin so that time for an insulin intervention
is dependent on local clinicians; patient age at adult liver trans-
plantation is usually beyond 35 years; BMI is always low in
chronic consumption such as cirrhosis, but can increase in cirrho-
sis with massive ascites and edema. Therefore, further well-
designed and large sample studies are needed to evaluate the
LADA-associated characters in NODAT and to explore the possible
correlation. Studying the association between TCF7L2 gene and
clinical parameters (e.g., islet cell autoantibodies, insulin resis-
Open access under CC BY-NC-ND license.13 vol. 58 j 1053–1061
tance, b-cell function, tacrolimus response, antidiabetic response)
in liver transplantation can provide more valuable information.
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